GlassScriptPhysician profile
Brendan Tran
NPI 1568039758
$1,701.47
in general payments reported to CMS, 2019-2025
18 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $24.28 · 2024: $380 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $255.08 | 2025 | Rezdiffra |
| Novo Nordisk INC | $213.83 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $185.37 | 2024-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $183.09 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $161.15 | 2025 | |
| Lilly USA, LLC | $155.52 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Viatris Specialty LLC | $152.28 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $76.09 | 2023-2025 | Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $68.78 | 2024-2025 | Tezspire, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $56.48 | 2025 | |
| Seqirus USA INC | $33.56 | 2025 | Flucelvax, Fluad |
| Mylan Specialty L.P. | $28.93 | 2024 | Yupelri |
| Medtronic, INC. | $26.61 | 2025 | Venaseal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.31 | 2025 | Xifaxan |
| Ardelyx, INC. | $22.60 | 2025 | Ibsrela |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21.29 | 2025 | Voquezna |
| Ani Pharmaceuticals, INC. | $19.71 | 2025 | Purified Cortrophin Gel |
| Sumitomo Pharma America, INC. | $17.79 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brendan Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.